about
The clinical significance of tenascin-C splice variant expression in chondrosarcomaThrombotic thrombocytopenic purpura in the setting of systemic sclerosis.Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase Cdelta pathways in human adult articular chondrocytesWalking barefoot decreases loading on the lower extremity joints in knee osteoarthritis.Osteogenic protein 1 in synovial fluid from patients with rheumatoid arthritis or osteoarthritis: relationship with disease and levels of hyaluronan and antigenic keratan sulfate.Asymmetries and relationships between dynamic loading, muscle strength, and proprioceptive acuity at the knees in symptomatic unilateral hip osteoarthritisThe role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors.Asymmetric loading and bone mineral density at the asymptomatic knees of patients with unilateral hip osteoarthritisThe treatment of psoriatic arthritis.New therapeutic approaches for spondyloarthritis.Reduced lower extremity vibratory perception in osteoarthritis of the knee.Patient reported outcomes and analgesia use in osteoarthritis of the knee.Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.The biomechanics of osteoarthritis: implications for therapy.Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.The effects of oral glucosamine on joint health: is a change in research approach needed?Lower limb osteoarthritis: biomechanical alterations and implications for therapy.Tuberculosis infections and tumor necrosis factor alpha antagonists.Corticosteroid Monotherapy Is Usually Insufficient Treatment for Idiopathic Inflammatory Myopathy.Radiocarpal and first metatarsophalangeal intraarticular injection site confirmation with fluoroscopy and review of accuracy of intraarticular injections.Serum transaminases are frequently elevated at time of diagnosis of idiopathic inflammatory myopathy and normalize with creatine kinase.Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.Practice patterns in longitudinal lupus care provision: patient and physician perspectives.Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?Retrospective Study of Patients on Etanercept Therapy for Rheumatic Diseases in Patients With Chronic Hepatitis C Virus.Improved precision in quantifying knee alignment angle.Education, zip code-based annualized household income, and health outcomes in patients with systemic lupus erythematosus.Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells.Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line.Nonrandom evolution of end-stage osteoarthritis of the lower limbs.Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma.Hemorrhagic cystitis complicating untreated necrotizing vasculitis.Tenascin-C expression and distribution in cultured human chondrocytes and chondrosarcoma cells.Lupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosus.Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin.Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma.
P50
Q28207508-96F0B10D-530F-4048-91D3-8CD47B54522DQ33364837-AEA0D0D1-C8A8-4042-995A-7475233A230DQ33915660-9F66E011-4526-442B-975C-4AFDA4143214Q33953872-E4252122-96A1-4DA9-88FD-A2988D4DC269Q34562659-B11CAFAA-F681-4D02-9293-AA358F7A8812Q34897305-25E45738-979F-4DE3-9943-A6F74EC9BCE4Q34981340-4072A656-53AA-4486-86D3-622B0F8D71CFQ35092953-5188E9F2-64FD-4B8F-A346-2FAAA04FD312Q35602509-014B4E35-02C2-40BC-AE92-B60A12351FDEQ36374823-059834BF-CCF2-4EC5-8BC9-E5192D110149Q36784024-12301899-2EC4-479C-8516-F04B9B3813CEQ36841769-3379411B-3DC0-4C6D-8503-C44AA04DAD16Q36983784-D8A93EF8-5CD6-42F4-A758-143EE98A1214Q37068572-07FF80BA-DCD3-4368-BC29-25348F54E5E0Q37378092-EA101C40-D011-47C4-8FCF-CE3BE33139DEQ37427138-AF4736E8-14AE-4A25-9D8C-BFDD4F97B454Q37592565-997AF242-EEEC-4C2F-82DC-CA57B547566FQ37769078-18A30B32-DB79-414E-90D5-789E81E6B244Q37868859-75DD18B8-47FA-4AC7-9B9A-91B3AEB5684AQ38116789-AB987538-992C-453F-9691-BDDE55D984E5Q38122517-19D0995E-5911-41AF-8029-7E01B21BD5E9Q38198890-73A391D6-3BB5-4E32-89B0-6BC657CA315BQ38285761-10C2771D-28C4-4C61-857B-8CDCB65DE686Q38704098-1C2FA253-B740-4C29-947C-1BF5931F9629Q38817280-B72BE73C-16D6-4D1F-A2AE-7578A37DD0E8Q39430815-BCBCE574-C386-47D1-BCEC-66A5A0917175Q39783885-C804A619-39A9-4CE8-BA7B-7DA6C83F263CQ39886577-164C2277-DF88-44A4-9148-1E453DA8FB90Q40162246-0E8105EC-C204-4CC6-93A6-14AB1BA7473FQ40172789-12AF09BF-BA16-4D37-83EB-8854D1F11A3BQ40500999-823B9125-0CAD-41A8-B9FF-3240F2BEAF46Q40615480-357D465F-0B48-4733-AA22-0870E9FFEC06Q40626972-938E0668-5646-4C64-B69E-D59477198246Q40710383-303EDF96-24DD-4D19-8D92-891526D71532Q40711936-81769709-B13A-4379-B73C-17B5C0EE0427Q40750370-CB39CF72-339E-4E2B-B09B-19087ACDF901Q40779289-F2A98EC2-5487-4335-9AFA-467D4E102E78Q40808823-EF6EE6D9-6123-4A70-9F32-AB75CF64CBA3Q41183571-AED8729F-5F3B-4698-824E-E8B04D6DCE6EQ41183582-1107C908-3CC7-42CE-860D-11AEA5813508
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joel A Block
@ast
Joel A Block
@en
Joel A Block
@es
Joel A Block
@nl
type
label
Joel A Block
@ast
Joel A Block
@en
Joel A Block
@es
Joel A Block
@nl
prefLabel
Joel A Block
@ast
Joel A Block
@en
Joel A Block
@es
Joel A Block
@nl
P106
P21
P31
P496
0000-0002-0330-7353